Xintong Medical-B (02160) rose more than 7%. As of press release, it rose 7.46% to HK$1.44, with a turnover of HK$3.685,400.
The Zhitong Finance App learned that Xintong Medical-B (02160) rose by more than 7%. As of press release, it had risen 7.46% to HK$1.44, with a turnover of HK$3.685,400.
According to the news, Xintong Medical announced that the Group expects revenue of RMB 330 million to RMB 340 million for the year ended December 31, 2023, an increase of about 31% to 36% over the revenue of RMB 251 million for the year ended December 31, 2022. Revenue growth is mainly due to continued progress in the admission of transcatheter aortic valve implantation TAVI products in China, driving rapid increases in implantation volume and revenue, as well as overseas market expansion and revenue growth.